Express Scripts Holding Co (NASDAQ:ESRX) – William Blair increased their FY2018 earnings per share estimates for Express Scripts in a report released on Wednesday, October 31st. William Blair analyst J. Kreger now forecasts that the company will post earnings of $9.08 per share for the year, up from their prior forecast of $9.07. William Blair currently has a “Market Perform” rating on the stock. William Blair also issued estimates for Express Scripts’ Q3 2019 earnings at $2.51 EPS, FY2019 earnings at $9.74 EPS, FY2020 earnings at $8.05 EPS and FY2021 earnings at $6.96 EPS.
Express Scripts (NASDAQ:ESRX) last issued its earnings results on Wednesday, October 31st. The company reported $2.43 EPS for the quarter, topping the Zacks’ consensus estimate of $2.42 by $0.01. The business had revenue of $25.56 billion for the quarter, compared to analyst estimates of $25.11 billion. Express Scripts had a net margin of 4.83% and a return on equity of 25.43%. The company’s quarterly revenue was up 3.6% compared to the same quarter last year. During the same period last year, the company posted $2.51 earnings per share.
ESRX has been the topic of a number of other reports. Royal Bank of Canada set a $101.00 target price on shares of Express Scripts and gave the stock a “buy” rating in a research report on Thursday, November 1st. ValuEngine raised shares of Express Scripts from a “hold” rating to a “buy” rating in a research report on Monday, September 17th. Robert W. Baird lowered shares of Express Scripts from an “outperform” rating to a “neutral” rating and set a $81.00 target price on the stock. in a research report on Friday, July 20th. BidaskClub raised shares of Express Scripts from a “buy” rating to a “strong-buy” rating in a report on Friday, October 12th. Finally, Leerink Swann set a $100.00 price objective on shares of Express Scripts and gave the company a “hold” rating in a report on Thursday, November 1st. Two investment analysts have rated the stock with a sell rating, thirteen have issued a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. Express Scripts has a consensus rating of “Hold” and a consensus price target of $89.07.
Shares of NASDAQ:ESRX opened at $98.19 on Monday. The company has a market cap of $54.55 billion, a PE ratio of 13.83, a P/E/G ratio of 1.22 and a beta of 0.89. Express Scripts has a one year low of $59.17 and a one year high of $98.98. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.65 and a current ratio of 0.77.
In related news, insider Christine Houston sold 12,898 shares of Express Scripts stock in a transaction that occurred on Friday, August 10th. The shares were sold at an average price of $85.00, for a total transaction of $1,096,330.00. Following the transaction, the insider now directly owns 110,908 shares of the company’s stock, valued at $9,427,180. The sale was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 0.79% of the company’s stock.
A number of hedge funds have recently modified their holdings of ESRX. TRUE Private Wealth Advisors acquired a new stake in Express Scripts in the third quarter valued at approximately $115,000. Palo Capital Inc. acquired a new stake in Express Scripts in the third quarter valued at approximately $124,000. Landaas & Co. WI ADV acquired a new stake in Express Scripts in the second quarter valued at approximately $102,000. Kaizen Advisory LLC boosted its stake in Express Scripts by 147.6% in the second quarter. Kaizen Advisory LLC now owns 1,342 shares of the company’s stock valued at $104,000 after acquiring an additional 800 shares in the last quarter. Finally, Adviser Investments LLC boosted its stake in Express Scripts by 321.9% in the second quarter. Adviser Investments LLC now owns 1,481 shares of the company’s stock valued at $114,000 after acquiring an additional 1,130 shares in the last quarter. 84.20% of the stock is currently owned by institutional investors.
About Express Scripts
Express Scripts Holding Company operates as a pharmacy benefit management (PBM) company in the United States and Canada. The company's PBM segment offers clinical solutions; and specialized pharmacy care, home delivery and specialty pharmacy, retail network pharmacy administration, benefit design consultation, drug utilization review, drug formulary management, public exchange, administration of group purchasing organization, and digital consumer health and drug information services.
Recommended Story: What is a Tariff?
Receive News & Ratings for Express Scripts Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Express Scripts and related companies with MarketBeat.com's FREE daily email newsletter.